.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Deepinder Goyal recently introduced the Entropy biomarker, claiming it can measure the real-time cost of being alive. Specifically, this new health metric comes from his health-tech wearable startup, Temple. Indeed, the system tracks metabolic expenditure continuously. A live interface displays the score on a scale from 1 to 250, updating every second. While lower scores indicate deeper states of rest, higher scores represent peak physical exertion. Furthermore, Temple claims that fit meditators achieve the lowest numbers, while elite athletes reach the maximum score.
However, the medical community in India has raised significant concerns about these claims. Specifically, Dr. Suvrankar Datta, a radiologist at AIIMS Delhi, previously criticized the device as having zero scientific standing as a medical instrument. Moreover, they point out that Temple has not published any peer-reviewed scientific validation. Therefore, healthcare professionals view the device as an unproven consumer toy rather than a clinical tool. Consequently, medical practitioners warn patients not to rely on such proprietary scores for clinical decisions.
Moreover, Temple's longevity framework introduces two baseline targets: Entropy Maxima and Entropy Minima. The company asserts that users should strive to increase their maximum physical capacity. Meanwhile, they should try to reduce their resting metabolic cost over time. Specifically, Goyal argues that a lower resting cost of being alive correlates with a longer lifespan across the animal kingdom. Consequently, the startup positions this metric as a revolutionary tool for longevity. However, without independent clinical trials, these theories remain speculative in the scientific community.
Additionally, the global market for fitness wearables is expanding rapidly. Leading devices from companies like WHOOP, Oura, and Garmin already estimate physiological load and recovery. Unlike these wristbands or rings, Temple's device reads signals exclusively from the forehead or temple region. Therefore, it aims to capture unique localized physiological data. Nevertheless, doctors emphasize that consumer tech must undergo rigorous scientific testing before claiming any clinical utility.
Q1: What is the Entropy biomarker claimed by Temple?
The Entropy biomarker is a proprietary metric introduced by Deepinder Goyal's startup, Temple. It claims to calculate the body's real-time metabolic cost on a scale of 1 to 250.
Q2: Is the Entropy biomarker medically validated?
No, the metric currently lacks peer-reviewed scientific studies, clinical validation, or official medical clearance.
Q3: Why did AIIMS Delhi radiologist Dr. Suvrankar Datta criticize the device?
Dr. Datta criticized the wearable for having zero scientific standing as a medical instrument, describing it as a fancy toy for billionaires.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Deepinder Goyal's health startup Temple claims to have discovered the 'Entropy' biomarker to measure the body's real-time metabolic cost. However, Indian medical experts, including AIIMS Delhi radiologists, have criticized the wearable's clinical validity, highlighting the lack of peer-reviewed validation.
2 months ago
A nationwide mixed-methods study evaluated hospital glycemic management systems across 265 hospitals. While real-time alerts and automatic data sync are highly valued, significant disparities in digital maturity and low satisfaction with decision support highlight the need for standardized implementation.
Last week
Private equity firm LeapFrog Investments plans to deploy up to $100 million across Indian healthcare over the next two years. The capital will target asset-light delivery models, non-metro hospital networks, diagnostics, and single-specialty clinical infrastructure.
Last week
The Food Safety and Standards Authority of India has proposed front-of-pack warning labels with a red hexagonal graphic for packaged items high in sugar, fat, or salt. This critical public health initiative aims to combat non-communicable diseases and empower consumers across the country.
Last week
Nearly 80% of Indians suffer from inadequate Vitamin D, causing silent bone weakening and sudden fractures. This expert guide reviews why mega-dose therapy is critical for high-risk patients, the key factors driving widespread deficiency, and the mandatory medical evaluations needed to protect skeletal health.
2 months ago
The Supreme Court of India has sharply criticized the Food Safety and Standards Authority of India for delaying front-of-package warning labels. With non-communicable diseases causing over 6 million deaths annually, clear nutritional warnings are critical to combat childhood obesity, diabetes, and cardiovascular risk.
3 weeks back
